ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion
and analysis of the results of operations and financial condition of Sentient Brands Holdings Inc. for the nine months ended September
30, 2021 and 2020 should be read in conjunction with the Sentient Brands Holdings Inc. unaudited condensed consolidated financial statements
and the notes thereto contained elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations
that involve risks and uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events
could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those
set forth under the Risk Factors, Special Note Regarding Forward-Looking Statements and Business sections in our Form 10-K as filed with
the Securities and Exchange Commission on April 15, 2021. We use words such as “anticipate,” “estimate,” “plan,”
“project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,”
“may,” “will,” “should,” “could,” and similar expressions to identify forward-looking
statements .
Unless otherwise indicated, references to the “Company,”
“us” or “we” refer to Sentient Brands Holdings Inc. and its subsidiaries.
Overview
Sentient Brands is a next-level product development
and brand management company with a focus on building innovative brands in the Luxury and Premium Market space. The Company has a Direct-to
Consumer business model focusing on the integration of CBD, wellness and beauty for conscious consumers. The Company incorporates an omnichannel
approach in its marketing strategies to ensure that its products are accessible across both digital and retail channels. The Company develops
and nurtures Lifestyle Brands with carefully thought-out ingredients, packaging, fragrance and design. Sentient Brands’ leadership
team has extensive experience in building world-class brands such as Hugo Boss, Victoria’s Secret, Versace, and Bath & Body
Works. The Company is focused on two key market segments targeting: wellness and responsible luxury, which the Company believes represent
unique opportunities for its Oeuvre product line. Sentient Brands intends to leverage its in-house innovation capabilities to launch new
products that “disrupt” adjacent product categories. We plan to grow by leveraging our deep connections within our existing
network and attract consumers through increased brand awareness and investing in unique social media marketing. The Company’s goal
is to create customer experiences that have sustainable resonance with consumers and consistently implement strategies that result in
long-term profit growth for our investors.
Principal Products and Services
The Company currently has one main product
line and two other product lines in development. The Company’s current active product line is Oeuvre.
Oeuvre
Oeuvre - ”A Body of
Art” – is the next product line that we plan to launch in the fourth quarter of 2021 and is intended to
be a next generation CBD luxury skin care line and lifestyle brand. Planned product offerings under the Oeuvre product
line include:
|
●
|
Purifying Exfoliator
|
|
●
|
Replenishing Oil
|
|
●
|
Ultra-Nourishing Face Cream
|
|
●
|
Revitalizing Eye Cream
|
|
●
|
High Potency Tincture
|
|
●
|
CBD infused and scented candles
|
|
●
|
CBD infused women’s fragrance
|
Drawing inspiration from petals, leaves, roots, minerals,
and gemstones, Oeuvre celebrates the artistry of well-being and beauty, inside and out. Oeuvre products
are non-toxic, ungendered products made with zero GMO, retinyl palmitate, petroleum, mineral oil, parabens, sulfates, and synthetic colors.
Oeuvre Target Market
Oeuvre is planned to be our luxury
segment product line. With Oeuvre, we are targeting a large and influential consumer class of individuals that are
“HENRYs” – High-Earners-Not-Rich-Yet. These individuals have discretionary income and may be wealthy in the future.
HENRYs earn between $100,000 and $250,000 annually. They are typically digitally fluent, are frequent online shoppers, and are
discretionary spenders. Our website, ouvreskincare.com, offers inclusive, aspirationally affordable luxury products positioned
for such consumers.
We believe the benefit of onboarding this consumer
demographic to Oeuvre are twofold: securing valuable present customers and building relationships and business
with those most likely to be among affluent consumers in the future. By the year 2025, Millennials and Generation Z reportedly
will represent more than 40% of the overall luxury goods market, according to a 2019 report published by Boston Consulting Group.
We seek to target such consumer group for the sale of our Oeuvre products.
On social media, we will target the following
audiences for the Oeuvre brand:
|
●
|
Women aged 30+
|
|
●
|
Luxury Skincare Enthusiasts
|
|
●
|
CBD Enthusiasts
|
|
●
|
Crystal Lovers
|
|
●
|
Wellness Audience
|
|
●
|
Makeup Artists
|
|
●
|
Art
|
|
●
|
Beauty
|
|
●
|
Influencers
|
|
●
|
Bloggers
|
|
●
|
Stores
|
Future Product Lines
The Company has two product lines planned for introduction
by the end of 2021:
|
●
|
F.A.M.E. - a millennial, premium priced dual-gender lifestyle brand
|
|
●
|
LevelLab – a premium priced millennial fitness/wellness/performance product line
|
LevelLab
We intend LevelLab to be a premium-priced millennial fitness, wellness, and performance product
line. Planned LevelLab products include:
|
●
|
LevelLab Therapeutic
Recovery Cream, which provides heating and cooling effects to sooth pain, containing isolate hemp CBD, and 100% THC free.
|
|
●
|
LevelLab Bundle including daily
facial cleanser, hyaluronic and vitamin C moisturizer, and retinol night cream.
|
|
●
|
LevelLab Active Hydration – supplement
for mineral replenishment and optimal hydration for before, during, and after workout.
|
|
●
|
LevelLab Fuel – a
recovery drink containing a unique combination of CBD and amino acids.
|
LevelLab Target Market
We plan to target Millennials (generally ages
23 – 38 as of 2019) for our LevelLab product line. These consumers, who became adults in a hyper-connected,
digital world, have unique shopping preferences, spend their time in different mediums, and respond to a different technology-driven
style of messaging than generations past. This evolution in consumer behavior accompanies a significant transition of purchasing
power to the Millennial generation. According to the 2015 U.S. Census Bureau, Millennials accounted for more than 25% of the U.S.
population, exceeding the number of baby boomers and making it the largest percentage of the workforce in the United States. Further,
according to the U.S. Bureau of Labor Statistics, people born after 1981, including Millennials and Generation Z, accounted for
approximately $1.7 trillion or 22% of the nation’s total consumer expenditure in 2017. We expect this number to significantly
increase as Millennials enter their peak earning years and an increasing percentage of Generation Z joins the workforce.
F.A.M.E
F.A.M.E. will merge health and
wellness with art and entertainment to curate unique and impactful products, content, and activities for a global community. As
stated in a 2017 article on the Wellness industry published by Forbes, 72% of millennials would rather spend money on experiences
than on material goods. With F.A.M.E., we intend to provide them with both. Products and offerings under the F.A.M.E. brand
name are currently under development.
F.A.M.E Target Market
The target market for F.A.M.E. is
also Millennials. We intend to market F.A.M.E. to premium consumers – both male and female – in the Millennial
market.
Suppliers
The Company has several third-party suppliers
and is not reliant on any particular supplier for its product offerings. Many of our products contain CBD derived from industrial
hemp or cannabis which we obtain from third parties. Hemp cultivation can be impacted by weather patterns and other natural events,
but we have not yet faced any supply issues in obtaining raw materials for our products.
Distribution
We have two primary methods through which we sell
our products:
|
1.
|
Direct to Consumer online e-commerce platform
|
|
2.
|
Wholesale partners
|
Marketing Strategy
We support brand launches with social media
and marketing campaigns, including utilizing influencers. Leading marketing and public relations firms are engaged by the Company
to spearhead the launch of Oeuvre, and will likely be engaged for our future planned brand launches as well.
Sentient Brands Growth Strategies:
In order to grow our Company, Sentient Brands
intends to:
|
●
|
Create a leading consumer packaged goods company;
|
|
●
|
Partner with established distributers and retailers;
|
|
●
|
Focus on operational excellence and product quality; and
|
|
●
|
Establish ongoing communication with the capital markets
|
Our mission is to create the next generation
of CBD consumer brands. The Company believes it has assembled a highly accomplished team of branding and marketing professionals
who have a combined experience and track record of successfully launching and operating major brands in the consumer market space,
which the Company believes will provide it with a competitive edge in the industry.
Customers
The Company launched its Oeuvre product line
in the fourth quarter of 2021. The Company’s sales channels are direct to consumer and wholesale.
Intellectual Property
The Company’s Oeuvre brand is
trademarked in the United States, with a European trademark application pending. The Company expects to rely on trade secrets
and proprietary know-how protection for our confidential and proprietary information, however we have not yet taken security
measures to protect this information.
Competition
We have experienced, and expect to continue
to experience, intense competition from a number of companies.
The current market for hemp-derived CBD products is
highly competitive, consisting of publicly-trade and privately-owned companies, many of which are more adequately capitalized than the
Company. The Company’s current publicly listed competitors include Charlotte’s Web, CV Sciences, Elixinol, Abacus, and Green
Growth Brands, and private companies such as BeBoe, St. Jane, Mary’s, Lord Jones, Bluebird Folium Biosciences, Global Cannabinoids,
and Pure Kana. In addition, public and private U.S. and Canadian companies have entered the hemp-derived CBD consumer market or have announced
plans to do so. This market is highly fragmented, and according to the Hemp Business Journal, the vast majority of industry participants
generate less than $2 million in annual revenue. We see this an opportunity to create a foothold in the CBD consumer marketplace with
the goal of building Sentient Brands as a major brand name in this space.
Industry Overview
The market for products based on extracts of
hemp and cannabis is expected to grow substantially over the coming years. Arcview Market Research and BDS Analytics are forecasting
the combined market to reach nearly $45 billion within the U.S. in the year 2024. While much of this market is expected to be comprised
of high potency THC-based products that will be sold in licensed dispensaries, certain research firms are still predicting the
market to grow to $5.3 billion, $12.6 billion, and $2.2 billion by 2024 for the product areas of low THC cannabinoids, THC-free
Cannabinoids and pharmaceutical cannabinoids, respectively.
We believe the recent passage of the 2018 Farm
Bill will allow the Company to expand its marketplace opportunities. On December 20, 2018, President Donald J. Trump signed into
law the Agriculture Improvement Act of 2018, otherwise known as the “Farm Bill.” Prior to its passage, hemp, a member
of the cannabis family, and hemp-derived CBD, were classified as a Schedule I controlled substances, and illegal under the Controlled
Substances Act (“CSA”). Under Section 10113 of the Farm Bill, hemp cannot contain more than 0.3 percent THC. THC refers
to the chemical compound found in cannabis that produces the psychoactive “high” associated with cannabis. Any cannabis
plant that contains more than 0.3 percent THC would be considered non-hemp cannabis or marijuana under federal law and would thus
face no legal protection under this new legislation and would be an illegal Schedule 1 drug under the CSA.
With the passage of the Farm Bill, hemp cultivation
is broadly permitted. The Farm Bill explicitly allows the transfer of hemp-derived products across state lines for commercial
or other purposes. It also puts no restrictions on the sale, transport, or possession of hemp-derived products, so long as those
items are produced in a manner consistent with the law.
Recent Developments
Covid-19
A novel strain of coronavirus (“Covid-19”)
emerged globally in December 2019 and has been declared a pandemic. The extent to which Covid-19 will impact our customers, business,
results and financial condition will depend on current and future developments, which are highly uncertain and cannot be predicted at
this time. While the Company’s day-to-day operations beginning March 2020 have been impacted, we have suffered less immediate impact
as most staff can work remotely and can continue to develop our product offerings.
On April 18, 2020, the Company, through its subsidiary
Jaguaring Company, entered into Paycheck Protection Program Promissory Note and Agreement with KeyBank National Association, pursuant
to which the Company received loan proceeds of $231,500 (the “PPP Loan”). The PPP Loan was made under, and is subject to the
terms and conditions of, the PPP which was established under the CARES Act and is administered by the U.S. Small Business Administration.
The term of the PPP Loan is two years with a maturity date of April 18, 2022 and contains a favorable fixed annual interest rate of 1.00%.
Payments of principal and interest on the PPP Loan will be deferred for the first six months of the term of the PPP Loan until November
18, 2020. Principal and interest are payable monthly and may be prepaid by the Company at any time prior to maturity with no prepayment
penalties. Under the terms of the CARES Act, recipients can apply for and receive forgiveness for all or a portion of loans granted under
the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for certain permissible purposes
as set forth in the PPP, including, but not limited to, payroll costs (as defined under the PPP) and mortgage interest, rent or utility
costs (collectively, “Qualifying Expenses”), and on the maintenance of employee and compensation levels during the eight-week
period following the funding of the PPP Loan. The Company has been using the proceeds of the PPP Loan, for Qualifying Expenses. However,
no assurance is provided that the Company will be able to obtain forgiveness of the PPP Loan in whole or in part.
Forward Stock Split / Increase of Authorized /
Name Change / Migratory Merger
On December 9, 2020, the Company filed a Certificate
of Amendment of Articles of Incorporation (the “Certificate”) with the State of California to (i) effect a forward stock split
of its outstanding shares of common stock at a ratio of 7 for 1 (the “Forward Stock Split”), (ii) increase the number of authorized
shares of common stock from 50,000,000 shares to 500,000,000 shares, and (iii) effectuate a name change (the “Name Change”).
Fractional shares that resulted from the Forward Stock Split will be rounded up to the next highest number. As a result of the Name Change,
the Company’s name changed from “Intelligent Buying, Inc.” to “Sentient Brands Holdings Inc.”. The Certificate
was approved by the majority of the Company’s shareholders and by the Board of Directors of the Company. The effective date of the
Forward Stock Split and the Name Change was March 2, 2021.
In connection with the above, the Company filed an
Issuer Company-Related Action Notification Form with the Financial Industry Regulatory Authority. The Forward Stock Split and the Name
Change was implemented by FINRA on March 2, 2021. Our symbol on OTC Markets was INTBD for 20 business days from March 2, 2021 (the “Notification
Period”). Our new CUSIP number is 81728V 102. As a result of the name change, our symbol was changed to “SNBH” following
the Notification Period.
In addition, on January 29, 2021, the Company, merged
with and into its wholly owned subsidiary, Sentient Brands Holdings Inc., a Nevada corporation, pursuant to an Agreement and Plan of Merger
between Sentient Brands Holdings Inc., a California corporation, and Sentient Brands Holdings Inc., a Nevada corporation. Sentient Brands
Holdings Inc., a Nevada corporation, continued as the surviving entity of the migratory merger. Pursuant to the migratory merger, the
Company changed its state of incorporation from California to Nevada and each share of its common stock converted into one share of common
stock of the surviving entity in the migratory merger. No dissenters’ rights were exercised by any of the Company’s stockholders
in connection with the migratory merger.
Following the consummation of the migratory merger,
the articles of incorporation and bylaws of the Nevada corporation that was newly-created as a wholly owned subsidiary of the Company
became the articles of incorporation and bylaws for the surviving entity in the migratory merger.
The foregoing information
is a summary of each of the matters described above, is not complete, and is qualified in its entirety by reference to the full text of
the exhibits, each of which is attached an exhibit to this Form 10-Q Quarterly Report. Readers should review those exhibits for a complete
understanding of the terms and conditions associated with this matter.
Government Regulation
The United States Food & Drug Administration (“FDA”)
is generally responsible for protecting the public health by ensuring the safety, efficacy, and security of (1) prescription and over
the counter drugs; (2) biologics including vaccines, blood & blood products, and cellular and gene therapies; (3) foodstuffs including
dietary supplements, bottled water, and baby formula; and, (4) medical devices including heart pacemakers, surgical implants, prosthetics,
and dental devices.
Regarding its regulation of drugs, the FDA process
requires a review that begins with the filing of an investigational new drug (IND) application, with follow on clinical studies and clinical
trials that the FDA uses to determine whether a drug is safe and effective, and therefore subject to approval for human use by the FDA.
Aside from the FDA’s mandate to regulate drugs,
the FDA also regulates dietary supplement products and dietary ingredients under the Dietary Supplement Health and Education Act of 1994.
This law prohibits manufacturers and distributors of dietary supplements and dietary ingredients from marketing products that are adulterated
or misbranded. This means that these firms are responsible for evaluating the safety and labeling of their products before marketing to
ensure that they meet all the requirements of the law and FDA regulations, including, but not limited to the following labeling requirements:
(1) identifying the supplement; (2) nutrition labeling; (3) ingredient labeling; (4) claims; and, (5) daily use information.
The FDA has not approved cannabis, marijuana, hemp
or derivatives as a safe and effective drug for any indication. As of the date of this filing, we have not, and do not intend to file
an IND with the FDA, concerning any of our products that contain CBD derived from industrial hemp or cannabis. Further, our products containing
CBD derived from industrial hemp are not marketed or sold using claims that their use is safe and effective treatment for any medical
condition subject to the FDA’s jurisdiction.
Government Approvals
The Company does not currently require any government
approvals for its operations or product offerings. In August 2019, the DEA affirmed that CBD preparations at or below the 0.3 percent
delta-9 THC threshold, is not a controlled substance, and a DEA registration is not required. As a result of the 2018 Farm Bill, the FDA
has been tasked with developing CBD regulations. The FDA has not yet published regulations.
Research and Development
We are continuously in the process of identifying
and/or developing potential new products to offer to our customers. Our expenditures on research and development have historically
been small and immaterial compared to our other business expenditures. We are currently developing new formulations for additional
product lines.
Employees
We believe that our success depends upon our ability
to attract, develop and retain key personnel. As of April 15, 2021, we employed 2 full-time employees. The Company otherwise currently
relies on the services of independent contractors. None of our employees are covered by collective bargaining agreements, and management
considers relations with our employees to be in good standing. Although we continually seek to add additional talent to our work force,
management believes that it currently has sufficient human capital to operate its business successfully.
Our compensation programs are designed to align the
compensation of our employees with our performance and to provide the proper incentives to attract, retain and motivate employees to achieve
superior results. The structure of our compensation programs balances incentive earnings for both short-term and long-term performance.
The health and safety of our employees is our highest
priority, and this is consistent with our operating philosophy. Since the onset of the COVID-19 pandemic, employees, including our specialized
technical staff, are working from home or in a virtual environment unless they have a requirement to be in the office for short-term tasks
and projects.
The primary mailing address for the Company is 555 Madison Avenue, 5th
Floor, New York, New York 10022. The Company’s telephone number is (646) 202-2897. The Company’s website is https://www.sentientbrands.com/.
RESULTS OF OPERATIONS
Comparison of Results of Operations for the Nine
Months ended September 30, 2021 and 2020
Revenue
We acquired Cannavolve on
February 14, 2020, where we consolidated our financial statements since then. The Company provides advisory and operational services to
hemp and ancillary cannabis companies, serving as a full-service business accelerator working with startups and emerging brands nationwide.
The Company accelerates customer’s businesses through a proven model of funding; operations; product launches; and ongoing sales,
marketing, and expansion into new markets. Each customer arrangement is unique, and revenue is recognized, both over time and at a point
in time, depending upon the performance obligations stated in the contract. During the nine months ending September 30, 2021, we did not
generate revenue compared to $19,219 for the nine month period ending September 30, 2020, due to the Company’s reorganization and
focus on the development of our new product lines and related marketing preparations.
Operating Expenses
For the nine months ended
September 30, 2021, and 2020, operating expenses consisted of the following:
|
|
2021
|
|
2020
|
Advertising and Marketing
|
|
|
12,800
|
|
|
|
32,162
|
|
Selling Expenses
|
|
|
—
|
|
|
|
22,020
|
|
General and Administrative
|
|
|
35,748
|
|
|
|
134,544
|
|
Legal and Professional
|
|
|
250,376
|
|
|
|
289,711
|
|
Office rent
|
|
|
824
|
|
|
|
16,351
|
|
Management Fees
|
|
|
63,000
|
|
|
|
100,140
|
|
Product development cost
|
|
|
3,153
|
|
|
|
26,200
|
|
Interest Expenses
|
|
|
38,841
|
|
|
|
|
|
TOTAL OPERATING EXPENSES
|
|
|
404,742
|
|
|
|
621,128
|
|
|
●
|
Our advertising and marketing costs mainly include consulting fees for branding, social media and creation of marketing materials for our brand. The decrease in advertising costs of $19,362, or by 60%, during the nine months period ending September 30, 2021 compared to the nine months ended September 30, 2020 was attributable to consulting fees for branding and marketing materials incurred for the nine months ended September 30, 2020.
|
|
●
|
Selling expense mainly includes our marketing and sales representative fees and related benefits, and travel and entertainment
costs incurred by our sales representatives.
|
|
●
|
Legal and professional fees primarily consisted of accounting fees, legal service fees, consulting fees, investor
relations service charges and other fees incurred for service related to becoming and being a public company. For the nine months
ended September 30, 2021, professional fees decreased compared to the same period in 2020 mainly attributable to a decrease in
fees of approximately $15,000 incurred for services performed by our marketing consultant. We expect professional fees to increase
as we incur significant costs associated with our public company reporting requirements, and costs associated with newly applicable
corporate governance requirements, including requirements under the Sarbanes-Oxley Act of 2002 and other rules implemented by the
Securities and Exchange Commission.
|
|
●
|
Office
rent expense is monthly lease payments for our principal executive offices in New York, New York .
|
|
●
|
Our management fees are comprised mainly of salaries paid to our management staff. During the nine month period ending September 30, 2021, management fees decreased by approximately $40,000 compared to the same period in 2020 mainly attributable to the resignation of an employee.
|
|
●
|
Product development cost includes packaging supplies and materials, design and marketing consultants. The decrease of approximately $23,047, or 88%, during the nine month period ending September 30, 2021 was mainly due to the cost of design of marketing materials incurred during the nine months ended September 30, 2020.
|
Loss from Operations
The Company’s operating loss for the
nine month periods ended September 30, 2021, and 2020 was $404,640 and $675,974, respectively. A decrease in operating loss of
approximately $206,778 or 34% compared to the previous nine months ended September 30, 2020 was primarily decreased in general
and administrative expenses of $98,796, legal and professional fees of $39,335, and management fees of $37,140. The primary reason
for the overall reduction in operating expenses was primarily due the efforts of management to streamline operations and focus
on the development of new product lines.
Income Taxes
We did not have any income
taxes expense for the nine months ended September 30, 2021, and 2020 since we incurred losses in these periods.
Net Loss
The Company’s net loss for the nine month period ended September
30, 2021, and 2020 was $404,469 and $611,418, respectively.
Liquidity and Capital
Resources
As of September 30, 2021, we had total current assets
of $291,633, consisting of $32,852 in cash and $258,781 in inventories. Our total current liabilities as of September 30, 2021, were $1,296,790.
We had a working capital deficit of $1,005,157 as of September 30, 2021, compared with a working capital deficit of $605,552 as of December
31, 2020.
Cash Flows from Operating Activities
Operating activities used $472,898 in cash for the
nine months ended September 30, 2021, compared with cash used of $675,974 for the nine months ended September 30, 2020. Our negative operating
cash flow for the nine months ended September 30, 2021, was largely the result of our net loss of $880,779, full payment of inventories
$258,781 and offset by decrease in advances from supplier $154,893 and loss on valuation of derivative liabilities $476,310. Our negative
operating cash flow of $675,974 for the nine months ended September 30, 2020, was largely the result of the result out net loss of $552,840,
changes in current assets and liabilities $126,899.
Cash Flows from Financing Activities
There were no cash flow from investment activities
for the nine months ended September 30, 2021, while in the same period ending September 30, 2020, we purchased office equipment for
$39,277.
Cash Flows from Financing Activities
Net cash flows provided by financing
activities during the nine months ended September 30, 2021, amounted to $437,492 compared with cash flows provided by financing activities
of $708,061 for the previous period ended September 30, 2020. Our positive cash flows for the nine months ended September 30, 2021, consisted
of proceeds from convertible loans payable of $306,199 and short-term loans $130,404. Our positive cash flows for the nine months ended
September 30, 2020, consisted of proceeds from issuance of common stock of $471,560, short term loan $256,5000 offset by $20,000 payments
to loans payable.
Going Concern
As of September 30, 2021, we have an accumulated deficit
of $2,358,357. Our ability to continue as a going concern is contingent upon the successful completion of additional financing arrangements
and our ability to achieve and maintain profitable operations. While we are expanding our best efforts to achieve the above plans, there
is no assurance that any such activity will generate funds that will be available for operations. These conditions raise substantial doubt
about our ability to continue as a going concern. These financial statements do not include any adjustments that might arise from this
uncertainty.
Covid 19
A novel strain of coronavirus (“Covid-19”)
emerged globally in December 2019 and has been declared a pandemic. The extent to which Covid-19 will impact our customers, business,
results and financial condition will depend on current and future developments, which are highly uncertain and cannot be predicted at
this time. While the Company’s day-to-day operations beginning March 2020 have been impacted, we have suffered less immediate impact
as most staff can work remotely and can continue to develop our product offerings. That said we have seen our business opportunities develop
more slowly as business partners and potential customers are dealing with Covid-19 issues, working remotely and these issues are causing
delays in decision making and finalization of negotiations and agreements.
Contractual Obligations and Off-Balance Sheet Arrangements
Contractual Obligations
We presently do not have
any contractual obligations.
Off-balance Sheet Arrangements
We presently do not have
off-balance sheet arrangements.
Inflation
The effect of inflation on
our revenue and operating results was not significant.